This study is timely because recent whole-genome sequencing studies have shown a high mutation rate of TP53 in OAC.19, 20 With whole-genome sequencing technologies still not used in clinical practice for personalised cancer treatment, targeted genomic approaches remain a valid area of investigation.58 This evidence concerns the gene TP53 and cancer.